In a striking move reshaping the music royalty landscape, U.S. based Concord Chorus Ltd. has clinched a deal to acquire British counterpart Hipgnosis Songs Fund for $1.4 billion. This all-cash agreement, announced on Thursday, will significantly expand Concord's music catalog by adding over 1.2 million songs.

Hipgnosis Agrees $1.4B Takeover By US Rival Concord: Financing the Future of Music

The acquisition, under the indirect control of Alchemy Copyrights LLC, is being financed by Concord through a blend of debt and equity orchestrated by Apollo Capital Management LP. Concord's intricate financial strategy includes a $1.16 per share offer—a robust 32.2% premium over Hipgnosis' last closing price.

Legal Luminaries and the Deal Dynamics

Leading the legal charge for Concord, Reed Smith LLP stands at the helm of the transaction. DLA Piper supports with its formidable team including international finance specialist Mark Dwyer and entertainment finance expert Robert Sherman. Additionally, Mourant Ozannes LLP manages legal matters for Concord in Guernsey.

Hipgnosis is receiving guidance from Shoosmiths LLP in the U.K., with corporate partners Nick McCarthy and Andrew Millar spearheading efforts. Furthermore, Carey Olsen LLP, through partner Tony Lane, advises the firm in Guernsey jurisdiction. Apollo’s financial maneuvers are directed by Latham & Watkins LLP.

Hipgnosis Agrees $1.4B Takeover By US Rival Concord: A Fair Price for a Rich Catalog

Bob Valentine, CEO of Nashville-based Concord, stated that the offer fairly values Hipgnosis' prestigious catalog, which features hits from icons like Ed Sheeran, Lady Gaga, and Nirvana. He emphasized the deal's potential to enhance value for artists, composers, and stakeholders across the board.

Strategic Shifts and Shareholder Sentiments

Triggered by a strategic review initiated last October after extensive shareholder dialogues, Hipgnosis expressed the urgent need for managerial and financial reforms. These discussions culminated in the current acquisition proposal, needing approval from at least 75% of Hipgnosis shareholders. The vote is scheduled for a general meeting around June 10, with expectations to finalize the deal in Q3 2024.

Regulatory Hurdles and Market Movements

Pending approvals from the European Commission and the U.K.'s Competition and Markets Authority, the acquisition's future is still under scrutiny. Meanwhile, Hipgnosis' stock witnessed a dramatic surge, leaping nearly 30% in Thursday's midday trading on the London Stock Exchange.

Hipgnosis Agrees $1.4B Takeover By US Rival Concord : Financial Advisors at the Helm

J.P. Morgan Cazenove is serving as the exclusive financial advisor to Concord, while Singer Capital Markets and Shot Tower Capital LLC play pivotal roles for Hipgnosis in financial advising and strategic valuation respectively.

This monumental acquisition promises to reshape the global music royalties market, pending regulatory approval and shareholder consent, setting a new competitive standard in the industry.